ClinicalTrials.gg
CompletedNCT06868082Updated Feb 9, 2026

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants

A Phase 1 interventional study of Solrikitug and Solrikitug in Healthy, sponsored by Uniquity One (UNI). Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Uniquity One (UNI) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Formulations of Subcutaneously Administered Solrikitug in Healthy Japanese and non-Japanese Participants

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Uniquity One (UNI) is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of initial screening, in general good health (age 18 to 55 years);
  • Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring
  • Participant must agree to use during the treatment period and until follow-up
  • Capable of giving signed which includes compliance with the requirements and restrictions of the study

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding during the study
  • Chronic infection
  • Treatment with prohibited medications.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort A Solrikitug

    Biological: Solrikitug

  • Experimental
    Cohort B Solrikitug

    Biological: Solrikitug

  • Experimental
    Cohort C Solrikitug

    Biological: Solrikitug

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Treatment-Emergent Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE) V4.0

    Time frame: 165 days

Secondary outcomes

  1. Serum concentration of solrikitug

    Pharmacokinetics (PK) of solrikitug in healthy participants

    Time frame: 112 days

  2. Concentration of Immunogenicity

    Immunogenicity profile of solrikitug in healthy participants

    Time frame: 112 days

07

Study locations

1 site
  • Research Site
    Brisbane, Queensland, Australia
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Feb 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 10, 2025
StartActual
Jun 20, 2025
Primary completionActual
Feb 2, 2026
CompletionActual
Feb 2, 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06868082
Lead sponsor
Uniquity One (UNI)
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Jun 20, 2025
Primary completion
Feb 2, 2026
Completion
Feb 2, 2026
Last update
Feb 9, 2026

Study contacts

Andrew Lee, MD
study chair · Uniquity One

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solrikitug

Start the discussion